Preferences help
enabled [disable] Abstract
Number of results
2013 | 8 | 6 | 822-829
Article title

Predictors of treatment response in patients with hepatitis C 1b genotype

Title variants
Languages of publication
Physical description
1 - 12 - 2013
6 - 12 - 2013
  • Department of Internal Medicine, University of Tartu, L. Puusepa 6, 51014, Tartu, Estonia
  • Department of Virology, National Institute for Health Development, Hiiu 42, 11619, Tallinn, Estonia
  • Department of Virology, National Institute for Health Development, Hiiu 42, 11619, Tallinn, Estonia
  • Department of Virology, National Institute for Health Development, Hiiu 42, 11619, Tallinn, Estonia
  • [1] World Health Organization Viral Cancers: Hepatitis C virus. Accessed 2010 May 28. Available from: URL:
  • [2] Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., et al., Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, 2005, 42(4), 962–973[Crossref]
  • [3] Lavanchy D., Evolving epidemiology of hepatitis C virus, Clin. Microbiol. Infect., 2011, 17(2), 107–115[Crossref][WoS]
  • [4] Esteban J.I., Sauleda S., Quer J., The changing epidemiology of hepatitis C virus infection in Europe, J. Hepatol., 2008, 48, 148–162[Crossref]
  • [5] Tallo T., Norder H., Tefanova V., Krispin T., Schmidt J., Ilmoja M., et al., Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominanting subtype with time, J. Med. Virol., 2007, 79(4), 374–382[WoS][Crossref]
  • [6] Zusinaite E., Krispin T., Raukas E., Kiiver K., Salupere R., Ott K., et al., Hepatitis C virus genotypes in Estonia, APMIS, 2000, 108(11), 739–746[Crossref]
  • [7] Tefanova V., Tallo T., Kutsar K., Priimgi L., Urgent action needed to stop spread of hepatitis B and C in Estonian drug users, Euro Surveill., 2006, 11, E060126.3
  • [8] Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B., Diagnosis, management, and treatment of hepatitis C: an update, Hepatology, 2009, 49, 1335–1374[Crossref]
  • [9] EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J. Hepatol., 2011, 55, 245–264
  • [10] Shiffman M.L., Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders, Curr. Gastroenterol. Rep., 2006, 8(1), 46–52[Crossref]
  • [11] Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 2001, 358, 958–965[Crossref]
  • [12] Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L. Jr, et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N. Engl. J. Med., 2002, 347, 975–982
  • [13] Hadziyannis S.J., Sette H.Jr., Morgan T.R., Balan V., Diago M., Marcellin P., et al., Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann. Intern. Med., 2004, 140(5), 346–355
  • [14] McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection, N. Engl. J. Med., 2009, 361(6), 580–593[WoS]
  • [15] Ferenci P., Optimal treatment duration for patients with HCV genotype 1 infection, J. Viral. Hepat., 2012, 19(Suppl 1), 7–13[Crossref]
  • [16] Yu J.W., Sun L.J., Zhao Y.H., Kang P., Yan B.Z., Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment, Int. J. Infect. Dis., 2011, 15(11), 740–746[Crossref]
  • [17] Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al., Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy, Hepatology, 2003, 37(3), 600–609[Crossref]
  • [18] Zeuzem S., Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann. Intern. Med., 2004, 140(5), 370–381
  • [19] Foster G.R., Fried M.W., Hadziyannis S.J., Messinger D., Freivogel K., Weiland O., Predicting of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin, Scand. J. Gastroenterol., 2007, 42(2), 247–255[WoS][Crossref]
  • [20] Hoofnagle J.H., Wahed A.S., Brown R.S.Jr., Howell C.D., Belle S.H., Virahep-C Study Group, Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection, J. Infect. Dis., 2009, 199(8), 1112–1120[Crossref]
  • [21] Saludes V., Bracho M.A., Valero O., Ardevol M., Planas R., Gonzalez-Candelas F., et al., Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors, PloS One, 2010, 5(11), e14132[Crossref]
  • [22] Puig-Basagoiti F., Forns X., Furcić I., Ampurdanés S., Giménez-Barcons M., Franco S., et al., Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C, J. Gen. Virol., 2005, 86(Pt 4), 1067–1075[Crossref]
  • [23] Villela-Nogueira C.A., Perez R.M., de Segadas Soares J.A., Coelho H.S., Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin, J. Clin. Gastroenterol., 2005, 39(8), 728–730[Crossref]
  • [24] Jacobson I.M., Brown R.S. Jr., Freilich B., Afdhal N., Kwo P.Y., Santoro J., et al., Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial, Hepatology, 2007, 46(4), 971–981[Crossref]
  • [25] Poordad F., Reddy K.R., Martin P., Rapid virologic response: a new milestone in the management of chronic hepatitis C, Clin. Infect. Dis., 2008, 46(1), 78–84[WoS][Crossref]
  • [26] Fried M.W., Hadziyannis S.J., Shiffman M.L., Messinger D., Zeuzem S., Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection, J. Hepatol., 2011, 55(1), 69–75[Crossref][WoS]
  • [27] Clark P.J., Thompson A.J., McHutchison J.G., IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies, Am. J. Gastroenterol., 2011, 106(1), 38–45[WoS][Crossref]
  • [28] Bedossa P., Poynard T., An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group, Hepatology, 1996, 24(2), 289–293[Crossref]
  • [29] Backus L.I., Boothroyd D.B., Phillips B.R., Belperio P., Halloran J., Mole L.A., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C, Clin. Gastroenterol. Hepatol., 2011, 9, 509–516[Crossref]
  • [30] Brjalin V., Salupere R., Tallo T., Kuznetsova T., Priimägi L., Tefanova V., Efficacy of peginterferon alfa-2a and ribavirin combination therapy in treatment-naïve Estonian patients with chronic hepatitis C, Cent. Eur. J. Public Health, 2012, 20(2), 150–155
  • [31] Lee S.S., Bain V.G., Peltekian K., Krajeden M., Yoshida E.M., Deschenes M., et al., Treating chronic hepatitis C with pegylated interferon alfa- 2a (40 KD) and ribavirin in clinical practice, Aliment. Pharmacol. Ther., 2006, 23, 397–408[Crossref]
  • [32] Mauss S., Hueppe D., John C., Goelz J., Heyne R., Moeller B., et al., Estimating the likelihood of sustained virological response in chronic hepatitis C therapy, J. Viral. Hepat., 2011, 18, 81–90[Crossref]
  • [33] Weich V., Herrmann E., Chung T.L., Sarrazin C., Hinrichsen H., Buggisch P., et al., The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection, J. Gastroenterol., 2011, 46(12), 1427–1436[WoS][Crossref]
  • [34] Marcellin P., Cheinquer H., Curescu M., Dusheiko G.M., Ferenci P., Horban A., et al., High sustained virologic response rates in rapid virologic response patients in the large realworld PROPHESYS cohort confirm results from randomized clinical trials, Hepatology, 2012, 56(6), 2039–2050[Crossref]
  • [35] Navaneethan U., Kemmer N., Neff G.W., Predicting the probable outcome of treatment in HCV patients, Therap. Adv. Gastroenterol., 2009, 2(5), 287–302[Crossref]
  • [36] Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al., Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa- 2a plus ribavirin, Gastroenteroly, 2006, 130, 1086–1097
  • [37] Lindsay K.L., Morishima C., Wright E.C., Dienstag J.L., Shiffman M.L., Everson G.T., et al., Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C, Clin. Gastroenterol. Hepatol., 2008, 6(2), 234–241[Crossref][WoS]
  • [38] Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al., Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection, N. Engl. J. Med., 1996, 334(2), 77–81[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.